此前有报道称微血管侵犯（MVI）与癌症预后有关；然而，其在双表型肝细胞癌（DPHCC）患者中的意义仍不清楚。我们研究了 MVI 对中国福建省诊断为 DPHCC 的患者生存的作用，该地区是 HCC 的高发地区。在联勤保障部队第 900 医院接受手术干预的 DPHCC 患者 (n = 84)使用对数秩检验和Kaplan-Meier方法对2013年至2019年的数据进行回顾性分析。还进行了单变量和多变量 Cox 模型分析，以进一步了解 MVI 与患者生存率之间的相关性。我们的结果表明，MVI 与生存率较差有关。单因素分析显示，MVI、肿瘤病灶数、坏死数、分化数、周围肝纤维化数、细胞角蛋白19（CK19）表达量、血清α-甲胎蛋白（AFP）和癌抗原199水平均表现出较强的相关性。与总生存期的相关性。根据多变量分析，坏死和血清 AFP 水平与死亡风险增加密切相关。肿瘤大小；肿瘤病灶的数量；差异化；周围性肝纤维化；肝被膜侵犯；根据 χ2 检验的结果，CK19、血管内皮生长因子、CK7 和粘蛋白 1 的表达与 MVI 相关。微血管侵犯可能与 DPHCC 患者的生存相关，并可能作为生存的预后预测因子。 © 作者 2023。由牛津大学出版社代表美国临床病理学会出版。版权所有。如需权限，请发送电子邮件至：journals.permissions@oup.com。

Microvascular invasion (MVI) has previously been reported to be related to cancer prognosis; however, its significance in patients with dual-phenotype hepatocellular carcinoma (DPHCC) remains uncharacterized. We studied the role of MVI in the survival of patients diagnosed with DPHCC in Fujian, China, which has a high incidence of HCC.Patients with DPHCC (n = 84) who had undergone surgical interventions at the 900th Hospital of the Joint Logistic Support Force between 2013 and 2019 were retrospectively analyzed using the log-rank test and Kaplan-Meier method. Univariate and multivariate Cox model analyses were also conducted to further understand the correlation between MVI and patient survival.Our results indicated that MVI was related to poor survival. According to the univariate analysis, MVI, the number of tumor lesions, necrosis, differentiation, peripheral hepatic fibrosis, the expression of cytokeratin 19 (CK19), and serum levels of both ɑ-fetoprotein (AFP) and cancer antigen-199 showed a strong correlation with overall survival. Necrosis and serum AFP levels were strongly related to an increased risk of death, according to the multivariate analysis. Tumor size; the number of tumor lesions; differentiation; peripheral hepatic fibrosis; liver capsule invasion; and expression of CK19, vascular endothelial growth factor, CK7, and mucin 1 showed a correlation with MVI, per the outcomes of χ2 tests.Microvascular invasion may correlate with the survival of patients with DPHCC and could potentially serve as a prognostic predictor of survival.© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.